Skeletal muscle relaxants for the treatment of myofascial pelvic pain and high tone pelvic floor disorders.
Journal
Current opinion in obstetrics & gynecology
ISSN: 1473-656X
Titre abrégé: Curr Opin Obstet Gynecol
Pays: England
ID NLM: 9007264
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
3
7
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Chronic pelvic main is a complex process that includes many causes. In gynecology, the treatment of myofascial pelvic pain and high tone pelvic floor disorders can be managed with skeletal muscle relaxants for select clinical indications. A review of skeletal muscle relaxants will be included for gynecologic indications. There are limited studies on vaginal skeletal muscle relaxants, but there can be oral forms used for chronic myofascial pelvic pain. They function as antispastic, antispasmodic, and combination of the two modes of action. Diazepam is the most studied for myofascial pelvic pain in both oral and vaginal formulations. Its use can be combined with multimodal management to optimize outcomes. Other medications have limitations due to dependency and limited studies that demonstrate improvement in pain scales. Skeletal muscle relaxants have limited high quality studies for chronic myofascial pelvic pain. Their use can be combined with multimodal options to improve clinical outcomes. Additional studies are needed for vaginal preparations and evaluation of safety and clinical efficacy for patient reported outcomes measures in patients living with chronic myofascial pelvic pain.
Identifiants
pubmed: 37387696
doi: 10.1097/GCO.0000000000000894
pii: 00001703-202308000-00007
doi:
Substances chimiques
Neuromuscular Agents
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-315Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mathias SD, Kuppermann M, Liberman RF, et al. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol 1996; 87:321–327.
Tu FF, As-Sanie S, Steege JF. Prevalence of pelvic musculoskeletal disorders in a female chronic pelvic pain clinic. J Reprod Med 2006; 51:185–189.
Kobayyashi H, Hasegawa Y. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharm Biopharm 1996; 311:29–35.
Fitzgerald CM, Neville CE, Mallinson T, et al. Pelvic floor muscle examination in female chronic pelvic pain. J Reprod Med 2011; 56:117–122.
Torosis M, Carey E, Christensen K, et al. A clinical consensus treatment algorithm for patients with high tone pelvic floor dysfunction: a Delphi Study of National Experts. Female Pelvic Med Reconstr Surg 2022; 6 (Supp 1):S1–S293.
See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy 2008; 28:207–213.
Dapas F, Hartman SF, Martinez L, et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine 1985; 10:345–349.
Casale R. Acute low back pain: symptomatic treatment with a muscle relaxant drug. Clin J Pain 1988; 4:81–88.
Friedman BW, Irizarry E, Solorzano C, et al. A Randomized, placebo-controlled trial of ibuprofen plus metaxalone, tizanidine, or baclofen for acute low back pain. Ann Emerg Med 2019; 74:512–520.
Crisp CC, Vaccaro CM, Estanol MV, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J 2013; 24:1915–1923.
Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52:139–150.
Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 1978; 3:72–91.
Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007; 50:428–441.
Larish AM, Dickson RR, Kudgus RA, et al. Vaginal diazepam for nonrelaxing pelvic floor dysfunction: the pharmacokinetic profile. J Sex Med 2019; 16:763–766.
Carrico DJ, Peters KM. Vaginal diazepam use with urogenital pain/pelvic floor dysfunction: serum diazepam levels and efficacy data. Urologic nursing 2011; 31:279–284. 299.
Holland MA, Joyce JS, Brennaman LM, et al. Intravaginal diazepam for the treatment of pelvic floor hypertonic disorder: a double-blind, randomized, placebo-controlled trial. Female Pelvic Med Reconstr Surg 2019; 25:76–81.
Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, et al. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J 2010; 21:895–899.
Murina F, Felice R, Di Francesco S, Oneda S. Vaginal diazepam plus transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 2018; 228:148–153.
Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Care Res 2004; 51:9–13.
Leite FM, Atallah ÁN, El Dib R, et al. Cyclobenzaprine for the treatment of myofascial pain in adults. Cochrane database of systematic reviews 2009; CD006830.
Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain 2002; 16:64–70.
Furtado RNV, Carazzato S, Farias CA, et al. Myofascial syndrome: comparison between infiltration of trigger points treatment and oral medication (cyclobenzaprine) [Síndrome 17yofascial: comparação entre o tratamento com infiltração de trigger points e medicação oral (ciclobenzaprina)]. Acta Fisiátrica 2002; 9:117–126.
Cashin AG, Folly T, Bagg MK, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with nonspecific low back pain: systematic review and meta-analysis. BMJ 2021; 374:n1446.
Abril L, Zamora C, Cordero M, et al. The relative efficacy of seven skeletal muscle relaxants. An analysis of data from randomized studies. J Emerg Med 2022; 62:455–461.
Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017; 76:318–328.
Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004; 51:9–13.
Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996–2013. Am J Public Health 2016; 106:686–688.
Soyka M. Treatment of benzodiazepine dependence. N Engl J Med 2017; 376:1147–1157.
Khan NF, Bykov K, Barnett ML, et al. Comparative risk of opioid overdose with concomitant use of prescription opioids and skeletal muscle relaxants. Neurology 2022; 99:e1432–e1442.
Chen C, Hennessy S, Brensinger CM, et al. Skeletal muscle relaxant drug-drug-drug interactions and unintentional traumatic injury: Screening to detect three-way drug interaction signals. Br J Clin Pharmacol 2022; 88:4773–4783.
Smink BE, Egberts AC, Lusthof KJ, et al. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs 2010; 24:639–653.
Acton EK, Hennessy S, Brensinger CM, et al. Opioid drug–drug–drug interactions and unintentional traumatic injury: screening to detect three-way drug interaction signals. Front Pharmacol 2022; 13:845485.
Dawwas GK, Hennessy S, Brensinger CM, et al. Signals of muscle relaxant drug interactions associated with unintentional traumatic injury: a population-based screening study. CNS Drugs 2022; 36:389–400.